Toll Free: 1-888-928-9744

Canavan Disease - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Canavan Disease - Pipeline Review, H1 2016


Global Markets Direct's, 'Canavan Disease - Pipeline Review, H1 2016', provides an overview of the Canavan Disease pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Canavan Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Canavan Disease
- The report reviews pipeline therapeutics for Canavan Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Canavan Disease therapeutics and enlists all their major and minor projects
- The report assesses Canavan Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Canavan Disease

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Canavan Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Canavan Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Canavan Disease Overview 6 Therapeutics Development 7 Pipeline Products for Canavan Disease - Overview 7 Pipeline Products for Canavan Disease - Comparative Analysis 8 Canavan Disease - Therapeutics under Development by Companies 9 Canavan Disease - Therapeutics under Investigation by Universities/Institutes 10 Canavan Disease - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Canavan Disease - Products under Development by Companies 13 Canavan Disease - Products under Investigation by Universities/Institutes 14 Canavan Disease - Companies Involved in Therapeutics Development 15 StemCells, Inc. 15 Turing Pharmaceuticals AG 16 Canavan Disease - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 HuCNS-SC - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Pegylated Aspartoacylase for Canavan Disease - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 TUR-007 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Canavan Disease - Recent Pipeline Updates 31 Canavan Disease - Dormant Projects 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
Number of Products under Development for Canavan Disease, H1 2016 7 Number of Products under Development for Canavan Disease - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Canavan Disease - Pipeline by StemCells, Inc., H1 2016 15 Canavan Disease - Pipeline by Turing Pharmaceuticals AG , H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Canavan Disease Therapeutics - Recent Pipeline Updates, H1 2016 31 Canavan Disease - Dormant Projects, H1 2016 42

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.